PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

Investors are growing impatient about a planned spinoff.

Why Shares of PAVmed Were Down This Morning

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results. Conference call to be held today at 4:30 PM EDT.

PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Lucid Diagnostics launches first Lucid test centers. Patients undergoing esophageal precancer testing in Phoenix metro area.

PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers

NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed's CEO, Lishan Aklog, will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT

PAVmed to Present at the 41st Annual Canaccord Genuity Growth Conference

NEW YORK--(BUSINESS WIRE)---- $PAVM--Prominent global industry executive Aster Angagaw has joined the Board of Directors of PAVmed's subsidiary, Lucid Diagnostics Inc.

Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors

NEW YORK--(BUSINESS WIRE)---- $pavm #earnings--PAVmed to hold business update conference call on August 12, 2021. Company conference call and webcast at EDT 4:30PM EDT.

CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021

PAVmed to Hold Business Update Conference Call on August 12, 2021

GT Biopharma Inc

Intec Parent

These Former Penny Stocks Are Turning Heads Ahead Of Robinhood IPO The post 3 Biotech Penny Stocks To Watch On Robinhood IPO Day appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch On Robinhood IPO Day

The company tapped a respected figure in its industry as a board vice chairman.

Why PAVmed Soared by 12% on Wednesday

NEW YORK--(BUSINESS WIRE)---- $pavm--Stanley Lapidus, former Chairman & CEO of Exact Sciences, joins PAVmed subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors.

Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors

NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed Subsidiary Lucid Diagnostics launches strategic partnership with direct-to-consumer telemedicine company UpScriptHealth.

PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth

PAVmed's main commercial-stage product, EsoCheck/EsoGuard, is a life-saving product addressing a $25bil market and is supported by Exact Sciences founder Stanley Lapidus.

PAVmed: A True Game-Changer For Medical Device Innovation

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology industry leader Tim Baxter, to its Board of Directors. Mr. Baxter will serve as Chair of the Company's Nomination Committee and as a member of its Audit Committee.

Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), has completed European IVDD CE Mark certification of its EsoGuard® Esophageal DNA Test (“EsoGuard”).

PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test

New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc.

PAVmed Launches Digital Health Company Veris Health Inc.

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid's EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ technology (“EsoCheck”) has received CE Mark certification.

PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its CarpX® minimally invasive carpal tunnel device.

PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device

Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics' EsoCheck and EsoGuard Technologies

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2021 Results - Earnings Call Transcript

Conference call to be held today at 4 :30 P M E D T

PAVmed Provides Business Update and First Quarter 2021 Financial Results

Dr. David Poppers to present on his initial experience with Lucid's EsoCheck and EsoGuard

PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021

Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization

PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team

Company conference call and webcast at 4:30 PM EDT

PAVmed to Hold Business Update Conference Call on May 17, 2021

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has appointed nationally recognized healthcare executive Jacque J. Sokolov to its Board of Directors (the “Board”). Dr. Sokolov will help establish and serve as the inaugural Chair of the Board's new Compliance & Quality Committee. He will also serve on Lucid's Audit and Compensation Committees.

News for PAVmed Stock (PAVM)